Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pancreatin is a mixture of digestive enzymes, including amylase, lipase, and protease, primarily derived from the porcine pancreas. It is used as an enzyme replacement therapy for patients with exocrine pancreatic insufficiency (EPI), a condition where the pancreas fails to secrete sufficient enzymes for proper digestion. This deficiency is commonly associated with cystic fibrosis, chronic pancreatitis, pancreatectomy, or gastrointestinal bypass surgery. By supplementing these essential enzymes, pancreatin facilitates the hydrolysis of fats into fatty acids and glycerol, starches into dextrins and sugars, and proteins into peptides. This process restores normal digestion, improves nutrient absorption, and alleviates symptoms such as steatorrhea and abdominal pain. Changzhou Qianhong Biopharma is a key producer of pancreatin API for global markets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pancreatin.